DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue.

  title={DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue.},
  author={Katrina Kos and Adam R Baker and Margareta Jern{\aa}s and Alison L. Harte and John C. Clapham and John P. O'Hare and Lena. Carlsson and Sudhesh Kumar and Phillip G McTernan},
  journal={Diabetes, obesity & metabolism},
  volume={11 4},
CONTEXT Dipeptidyl peptidase IV (DPP-IV) inactivates the incretin hormone glucagon-like peptide. It can also affect the orexigenic hormone neuropeptide Y (NPY(1-36)) which is truncated by DPP-IV to NPY(3-36), as a consequence NPY's affinity changes from receptor Y1, which mediates the antilipolytic function of NPY, to other NPY receptors. Little is known whether DPP-IV inhibitors for the treatment of type 2 diabetic (T2DM) patients could influence these pathways. AIMS To investigate the in… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 30 extracted citations

DPP4 in Diabetes

View 9 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 29 references

Separation of human adipocytes by size: hypertrophic fat cells display distinct gene expression.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology • 2006

Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.

The Journal of pharmacology and experimental therapeutics • 2005

Similar Papers

Loading similar papers…